Pressor therapy in critically III patients

Journal of Veterinary Emergency and Critical Care

Volumn 10, Issue 1, 2000, Pages 21-34

  Wohl, James S ^a   Clark, Terrence P ^b  

^a AUBURN UNIVERSITY   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0040009505     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2000.tb00003.x     Document Type: Article

References (113)

1. Ganong WF. Cardiovascular regulatory mechanisms. In: Review of Medical Physiology, 16th ed. Ed by WF Ganong, Norwalk, CT, Appleton & Lange, 1993, pp 538–550.
2. Parillo JE (moderator). Septic shock in humans. Advances in the understanding of pathgogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113:227–242, 1990.
3. Guyton AC. Physics of blood, blood flow, and pressure: Hemodynamics. In: Textbook of Medical Physiology, 7th ed. Ed by AC Guyton. Philadelphia, WB Saunders, 1986, pp 206–217.
4. Julien C, Zhang ZQ, Barres C. How sympathetic tone maintains arterial pressure. Fundam Clin Pharmacol 9:343–349, 1995.
5. Jordan D. Central integration of chemoreceptro afferent activity. In: Arterial chemoreceptors: Cell to system. Ed by RG O'Reagan, P Nolan, DS McQueen, DJ Paterson. New York, Plenium Press, 1994, pp 87–98.
6. Barroaco R, Ergene E, El-Ridi M. Purigenic receptors in the nucleus tractus solitarus mediate distinct cardiorepiratory response patterns. Drug Dev 28:309–314, 1993.
7. Jordan D, Mifflin SW, Spyer KM. Hypothalamic inhibition of neurons in the nucleus tractus solitarus of the cat is GABA mediated. J Physiol 399:389–404, 1988.
8. Berczi I. Neurohormonal defense in endotoxin shock. Annnals of the New York Academy of Sciences 840:787–802, 1998.
9. Cantin M, Genest J. The heart and the atrial natriuretic factor. Endocr Rev 6:107–127, 1985.
10. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49:153–179, 1991.
11. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from Larginine. Nature 333:664–666, 1988.
12. Moncada S, Palmer RMJ, Higgs A. Nitric oxide: physiology, pathophysiology and pharmacology. Parnacol Rev 43:109–141, 1991.
13. Titheradge MA. Nitric oxide in septic shock. Bioch Biophys Acta 1411:437–455, 1999.
14. Knowles RG, Moncada S. Nitric oxide as a signal in blood vessels. Trends Biochem Sci 17:399–402, 1991.
15. Curran RD, Billiar TR, Stuehr DJ, et al. Multiple cytokines are required to induce hepatocyted nitric oxide production and inhibit protein synthesis. Ann Surg 212:462–469, 1990.
16. Ceppi ED, Smith FS, Titheradge MA. Effects of multiple cytokines plus bacterial endotoxin on glucose and nitric oxide production by cultured hepatocytes. Biochem J 317:503–507, 1993.
17. Szabo C, Wu C, Gross S, et al. Interleukin-1-contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol 250:157–160, 1993.
18. Calver A, Collier J, Vallance P. Nitric oxide and cardiovascular control. Exp Physiol 78:303–326, 1993.
19. Mistry M, Nasjletti A. Prostanoids as mediators of prohypertensive and antihypertensive mechanisms. Am J Med Sci. 1988;31:263–267.
20. Masaki T, Miwa S, Sawamura T, et al. Subcellulkar mechanisms of endothelin of endothelin action in the vascular system. Eur J Pharmacol 375:133–138, 1999.
21. Simonson MS, Dunn MJ. Cellular signaling by peptides of the endothelin gene family. FASEB J 4:2989–3000, 1990.
22. Wilkins MR, Zhao L, Al-Tubuly R. The regulation of pulmonary vascular tone. Br J Pharmacol 42:127–131, 1996.
23. Butt AY, Higenbottam T. New therapies for primary pulmonary hypertension. Chest 105:21S–25S, 1994.
24. Zakheim RM, Molteni A, Mattioli L, et al. Plasma angiotensin II levels in hypoxic and hypovolemic stress in unanesthetized rabbits. J Appl Physiol 41:462–465, 1976.
25. Elton TS, Oparil S, Taylor GR, et al. Normobaric hypoxia stimulates endothelin- 1 gene expression in the rat. Am J Physio 1263:R1260–R1264, 1992.
26. Kouyoumdijan C, Adnot S, Levarne M, et al. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J Clin Invest 94:578–584, 1994.
27. Kitamura K, Kangawa K, Kawamoto M. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553–560, 1993.
28. Wang P, Ba ZF, Cioffi WG, et al. The pivotal role of adrenomedullin in producing hyperdynamic circulation in the early stages of sepsis. Arch Surg 133:1298–1304, 1998.
29. Jougasaki M, Wei CM, Heublin DM, et al. Immunohistochemical localization of adrenomedullin in canine heart and aorta. Peptides 16:773–775, 1995.
30. Hirata Y, Mitaka C, Sato K. Increased circulating adrenomedullin, a novel vasodilating peptide, in sepsis. J Clin Endocrinol Metab 81:1449–1453, 1996.
31. Nossaman BD, Feng CJ, Kaye AD, et al. Pulmonar vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not cats. Am J Physiol 270:L782–789, 1996.
32. Gattinoni L, Brazzi L, Pelosi P. A trial of goal oriented hemodynamic therapy in critically ill patients. N Engl J Med 333:1025–1032, 1995.
33. Snell RJ, Parillo JE. Cardiovasculkar dysfunction in septic shock. Chest 99:1000–1009, 1991.
34. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 24:163–172, 1996.
35. Horn KD. Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS). Q J Med 91:265–277, 1998.
36. Hotchkiss RS, Karl IE. Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. J Am Med Assoc 1503–1510, 1992.
37. McCluskey RS, Urbaschek R, Urbaschek B. The microcirculation during otoxemia. Cardio Res 32:752–763, 1996.
38. Rieschel ET, Brade H, Holst O, et al. Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol 216:39–81, 1996.
39. Zimmerman JJ, Ringer TV. Inflammatory response in sepsis. Crit Care Clin 8:163–189, 1992.
40. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock. Chest 103:565–575, 1993.
41. Bone RC. The pathogenesis of sepsis. Ann Intern Med 115:457–469, 1991.
42. Rackow EC, Astiz ME. Pathophysiology and 266:548–554, 1991.
43. Wenzel RP. The mortality of hospital acquired infections: need for new vital statistic Int J Epidemiol 17:225–227, 1988.
44. Gray GA, Furman BL, Parratt JR. Endotoxin induced impairmant of vascular reactivity in the pithed rat: Role of arachidonic acid metabolites. Circ Shock 31:395–406, 1990.
45. Bohm M. Catecholamine refractoriness and their mechanisms in cardiocirculatory shock and chronic heart failure. Thorac Cardiovasc Surg 46:270–276, 1998.
46. Bohm M, Kirchmayr R, Gierschik P, et al. Increase of myocardial inhibitory G-proteins in catecholamine refractory septic shock or in septic multiorgan failure. Am J Med 98:183–186, 1995.
47. Kato T, Bishop AT, Wood MB, et al. Effect of human adrenomedullin on vascular resistance in the canine tibia. J Orth Res 14:329–333, 1996.
48. Bellomo R, Cole L, Ronco C. Hemodynamic support and the role of dopamine. Kidney International 53:S71–S74, 1998.
49. Tisdale JE, Patel RV, Webb CR, et al. Proarrhythmic effects of intravenous vasopresors. Ann Pharmacother 29: 269–280, 1995.
50. Michel MC, Kenny B, Scwinn DA. Classification of alpha-1-adrenoceptor subtypes. Nauyn Schmiedebergs Arch Pharmacol 351:1–10, 1995.
51. Scwinn DA, Kwatra MM. Expression and regulation of alpha-1-adrenergic receptors in human tissues. Adv Pharmacol 42:390–394, 1998.
52. Bylund DB, Blaxall HS, Iversen LJ, Caron MG, Lefkowitz RJ, Lomasney, JW. Pharmacological characteristicsa of alpha-2 adrenergic receptors: Comparisons of pharmacologically defined subtypes identified by molecular cloning. Mol. Pharmacol. 1992:42 1–5.
53. Niznik HB, Liu F, Sugamori KS, et al. Expansion of the dopamine D1 receptor gene family. Defining molecular, Pharmacological, and funtional criteria for D1A, D1B, D1C, and D1D receptors. Adv Pharmacol 42:404–408, 1998.
54. Sibley DR, Monsma FJ. Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69, 1992.
55. Scwartz LB, Gewertz BL. The renal response to low dose dopamine. J Sug Res 45:574–588, 1989.
56. Carcoana OV, Hines RL. Is renal dose dopamine protective or therapeutic?. Yes. Crit Care Clin 12:677–685, 1996.
57. Berstein AD, Herach M, Cheung H, et al. The effect of various sympathomimetics on the regional circulations in hyperynamic sepsis. Surgery 112:549–561, 1992.
58. Scaher LG, Fink MP, Parillo JE. Norepinepherine alone of versus norepinephrin plus low-dose dopamine: Enhanced renal blood flow with combination pressor therapy. Crit Care Med 13:492–496, 1985.
59. D'Orio V, El Allaf D, Juchmes J, et al. The use of low dose dopamine in intensive care medicine. Arch Int Physiol Biochem 92:S11–S20, 1984.
60. Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen uptake and delivery in septic shock. Crit Care Med 23:1962–1970, 1995.
61. Schreuder WO, Schneider AJ, Groeneveld ABJ, et al. Effect of dopamine vs norepinephrine on hemodynamics in septic shock: Emphasis on right ventricular performance. Chest 95:1282–1288, 1989.
62. Chernow B, Roth BL. Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock 18:141–155, 1986.
63. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization on hyperdynamic sepsis. J Am Med Assoc 272:1354–1357, 1994.
64. Meier-Hellman A, Bredle DL, Specht M, et al. The effects of low dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 23:31–37, 1997.
65. Giraud GD, MacCannell KL. Decreased nutrient blood flow during dopamine and epinephrine induced intestinal vasodilation. J Pharmacol Exp Ther 230:214–220, 1984.
66. Marik PE. Gastric intramucosal pH. A better predictor of multiorgan dysfunction syndrome and death than oxygen-derived variables in patients with sepsis. Chest 104:225–229, 1993.
67. Carpati CM, Astiz ME, Rackow EC. Optimizing gastric mucosal perfusion: All catecholamines may not be created equal. Crit Care Med 25:1624–1625, 1997.
68. Anonymous. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med. 27:639–660, 1999.
69. Martin C, Perrin G, Saux P, et al. Effects of norepinephrine on right ventricular function in septic shock patients. Intensive Care Med 20:444–447, 1994.
70. Meier-Hellmann A, Sakke S, Reinhart K. Supportive therapy of the sepsis syndrome. Clin Chem Lab Med 37:333–339, 1999.
71. Karzzi W, Reilly JM, Hoffman WD, et al. Hemodynamic effect of dopamine, norepinephrine, and fluids in a dog model of sepsis. Am J Physiol 268:H692–H702, 1995.
72. Martin C, Saux P, Eon B, et al. Septic shock: A goal-directed therapy using volume loading, dobutamine, and/or norepinepherine. Acta Anaesthesiol Scand 34:413–417, 1990.
73. Anderdson Wp, Korner PI, Selig SE. Mechanisms involved in the renal responses to intravenous and renal artery infusions of noradrenaline in conscious dogs. J Physiol 321:21–30, 1981.
74. Martin C, Papazian L, Perrin G. Norepinephrine or dopamine for the treatment of hyperdyanmic septic shock. Chest 103:1826–1831, 1993.
75. Murakawa K, Kobayashi A. Effects of vasopresors on renal tissue gas tensions during hemorrhagic shock in dogs. Crit Care Med 16:789–792, 1988.
76. Redl-Wenzyl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 19:151–154, 1993.
77. Moran JL, O'Fathartaigh MS, Peisach AR, et al. Epinephrine as an inotropic agent in septic shock: A dose-profile analysis. Crit Care Med 21:70–77, 1993.
78. Mackenzie SJ, Kapdia F, Nimmo GR, et al. Adrenaline in treatment of septic shock: Effects on hemodynamics and oxygen transport. Intensive Care Med 17:36–39, 1991.
79. Meier-Hellman A, Reinhart K, Bredle DL, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 25:399–404, 1997.
80. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: A prospective, randomized study. Intensive Care Med 23:282–287, 1997.
81. Richardson PDI, Granger DN, Kvietys PR. Effects of norepinephrine, vasopressin, isoproterenol, and histamine on blood flow, oxygen uptake, and capillary filtration coefficient in the colon of the anesthetized dog. Gastroenterology 78:1537–1544, 1980.
82. Levy B, Bollaert P-E, Lucchelli J-P, et al. Dobutamine improves the adequacy of gastric mucosal perfusion in epinephrine-treated septic shock. Crit Care Med 25:1649–1654, 1997.
83. Smithies M, Yee TH, Jackson L, et al. Protecting the gut and the liver in the critically ill: Effects of dopexamine. Crit Care Med 22:789–795, 1994.
84. Cain SM, Curtis SE. Systemic and regional oxygen uptake and delivery and lactte flux in endotoxic dogs resuscitated with dextran and dopexamine or dextran alone. Circ Shock 38:173–181, 1992.
85. Hollingsworth HM, Giansiracusa DF, Upchurch KS. Anaphylaxis. J Intensive Care Med 6:55–70, 1991.
86. Brown C, Wiklund L, Bar-Joseph G, et al. Fututre directions for resuscitation research. IV Innovative advanced life support pharamcology. Resuscitation 33:163–177, 1996.
87. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med 19:1395–1400, 1991.
88. Yamazaki T, Shimada Y, Taenaka N, et al. Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. Crit Care Med 10:432–435, 1982.
89. Pollack CV. Utility of glucagon in the emergency department. J Emerg Med 11:195–205, 1993.
90. White CM. A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol 39:442–447, 1999.
91. Sauvadet A, Robin T, Pecker F, et al. Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Circ Res 78:102–109, 1996.
92. Love JN, Leasure JA, Mundt DJ, et al. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propanlol toxicity in a canine model. Clin Toxicol 30:399–412, 1992.
93. Kline JA, Tomaszewski CA, Schroder JD, et al. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther 267:744–750, 1993.
94. Lvoff R, Wilken DE. Glucagon in heart failure and in cardiogenic shock: experience with 50 patients. Circulation 45:534–542, 1972.
95. Bower MG, Okude S, Jolley WB, et al. Hemodynamic effects of glucagon. Arch Surg 101:411–415, 1970.
96. Barton P, Garcia J, Kouatli et al. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double blind, randomized, placebo-controlled, interventional study. Chest 109:1302–1312, 1996.
97. Lindner KH, Prengel AW, Strohmenger HU, et al. Vasopressin administration in refractory cardiac arrest. Ann Intern Med 124:1061–1064, 1996.
98. Lindner KH, Pregel AW, Pfenninger EG, et al. Vasopressin improves vital organ blood flow during closed chest cardiopulmonary resuscitation in pigs. Circulation 91:215–221, 1995.
99. Chugh SS, Lurie KG, Lindner KH. Pressor with promise. Using vasopressin in cardiopulmonary arrest. Circulations 96:2453–2454, 1997.
100. Morales D, Madigan J, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 100:226–229, 1999.
101. Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 62:275–279, 1986.
102. Saruta T. Mechanism of glucocorticoid-induce hypertension. Hypertens Res 19:1–8, 1996.
103. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A porspective, randomized, double blind, single center study. Crit Care Med 27:723–732, 1999.
104. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants Nat Biotechnol 17:545–549, 1999.
105. Rees DD, Palmer RMJ, Hodson HF, et al. A specific inhibitor of nitric oxide formation from Larginine attenuates endothelium-dependent relaxation. J Br Pharmacol 96:418–424, 1989.
106. Kilbourn RG, Gross SS, Jubran A, et al. NG-methyl-L-arginine inhibits tumor necrosis facto-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87:3629–3632, 1990.
107. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557–1558, 1991.
108. Cobb JP, Natanson C, Quezado ZM, et al. Differential hemodynamic effects of L-NMMA in endotoxemic and normal dogs. Am J Physiol 266:1634–1642, 1995.
109. Grover R, Lopez A, Lorente J, et al. Multicenter, randomized, placebo controlled, double blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. (Abstr) Crit Care Med 27:A33, 1999.
110. Rolfs JR, Bruner E, Chiu A, et al. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J Biol Chem 273:12128–12134, 1998.
111. Doyle M, Apostol I, Kerwin BA. Glutaraldehyde modification of recombinant human hemoglobin alters its hemodynamic properties. J Biol Chem 274:2583–2591, 1999.
112. Motterelini R, Foresti R, Vandegriff KD, et al. Oxidative stress response in vascular endothelial cells exposed to acellular hemoglobin solution. Am J Physiol 269:H648–H655, 1995.
113. Wink DA, Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, ctotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25:434–456, 1998.